ArticleCureus2026
Toward the Abandonment of Axillary Surgery: Is This the End of an Era?
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axillary surgery in breast cancer has evolved substantially from radical surgical approaches toward minimally invasive and, in selected cases, non-surgical strategies. This editorial summarizes emerging techniques for axillary staging, with particular emphasis on advanced imaging and optical spectroscopic methods, including contrast-enhanced ultrasonography, Raman spectroscopy, optical coherence tomography, Fourier-transform infrared spectroscopy, elastic scattering spectroscopy, and refractometry. These modalities demonstrate promising diagnostic accuracy and may allow for preoperative or intraoperative axillary staging, obviating the need for surgical excision. At the same time, ongoing randomized trials are investigating the omission of sentinel lymph node biopsy in carefully selected patients with early-stage breast cancer and clinically negative axillary lymph nodes. Early results suggest oncological safety in low-risk populations, although longer follow-up data are required. These developments suggest a future of personalized axillary management, potentially marking the beginning of the end for routine axillary surgery in breast cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.